At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- SYT-510 (drug), SYT-510 (drug), SYT-510 (drug), Placebo (drug)
- How long the study runs
- Study runs about 6 months (dates as stated)
- About the drug or intervention
- SYT-510 — drug: Oral formulation A fasted · SYT-510 — drug: Oral formulation B fasted · SYT-510 — drug: Oral formulation A fed · Placebo — drug: Oral formulation
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Testing a treatment
- Ages
- 18 Years to 65 Years
- Who
- All
- Number of participants
- 28
- Started
- 2024-11-04
- Last checked
- 2026-06
Plain English Summary
What is this study?
- • Testing a new treatment for healthy
- • Phase1 - 28 participants
- • Part 1 aims to investigate the relative bioavailability of a new formulation and to assess potential food effects following oral administration of SYT-510
Who can take part?
- • Ages 18 Years to 65 Years
- • Diagnosed with healthy
Where?
- • London - Richmond Pharmacology Ltd
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
Part 1 aims to investigate the relative bioavailability of a new formulation and to assess potential food effects following oral administration of SYT-510. Part 1 will then guide dosing in Part 2, a multiple dose study which aims to assess safety, tolerability and pharmacokinetic of multiple SYT-510 administrations.
Healthy
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Condition· Matched your search
Age· Tell us your age for better matching
Gender· Tell us your sex for better matching
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years - 65 Years
- Who can join: All genders
What the study is looking for
- ✓Males or females of non-childbearing potential (WOCBP) aged 18 to 65 years old (inclusive) at the date of signing...
- ✓Normal ECG, showing no clinically relevant deviations, as judged by the investigator.
- ✓Body mass index (BMI) between 18 and 30 kg/m2, inclusive, at Screening and Admission (e.g Day -1 or Day -2) and a...
Who cannot take part
- ✗Current or recurrent disease that as judged by the Investigator may interfere with the execution of the conduct of...
- ✗Laboratory parameters outside of the laboratory normal range.
- ✗Positive test results for alcohol or drugs of abuse.
- ✗Treatment with an investigational drug within 90 days preceding the first dose of trial medication.
- ✗Known or suspected intolerance or hypersensitivity to the the the study treatment, any closely related compound, or...
See the full criteria
Inclusion Criteria:
* Males or females of non-childbearing potential (WOCBP) aged 18 to 65 years old (inclusive) at the date of signing the informed consent form (ICF).
* Normal ECG, showing no clinically relevant deviations, as judged by the investigator.
* Body mass index (BMI) between 18 and 30 kg/m2, inclusive, at Screening and Admission (e.g Day -1 or Day -2) and a minimum weight of 50kg.
Exclusion Criteria:
* Current or recurrent disease that as judged by the Investigator may interfere with the execution of the conduct of the study.
* Laboratory parameters outside of the laboratory normal range.
* Positive test results for alcohol or drugs of abuse.
* Treatment with an investigational drug within 90 days preceding the first dose of trial medication.
* Known or suspected intolerance or hypersensitivity to the investigational product, any closely related compound, or any of the stated ingredients.
* History of significant allergic reactions (anaphylaxis, angioedema) to any product (food, pharmaceutical, etc).
* Current smokers and those who have smoked within the last 6 months.
Where Is This Study? (1 UK site)
Richmond Pharmacology Ltd
London, United Kingdom
Data sourced from ClinicalTrials.gov · Last verified: 2026-06